Daily BriefsECM

Daily Brief ECM: Aequitas: Wistron Corp GDR – Another Well Flagged US$1.5bn GDR and more

In today’s briefing:

  • Aequitas: Wistron Corp GDR – Another Well Flagged US$1.5bn GDR, Similar to Its Previous Offering
  • SB Energy Pre-IPO: Tearsheet
  • Aequitas: LuxNet GDR Early Look – Smallest Offering in the GDR Pipeline This Year
  • Aequitas: Shenzhen Longsys Electronics A/H Trading – One of the Lowest Insti Demand
  • Longsys (江波龙) IPO Trading
  • Aequitas: Elice IPO Pricing – Might Be Popular with Retail Investors
  • IPO Databook: Shenzhen Forms Syntron Information (HK) – Sep 2026
  • Pre-IPO Triapex Laboratories – Future Performance Will Lack Stability


Aequitas: Wistron Corp GDR – Another Well Flagged US$1.5bn GDR, Similar to Its Previous Offering

By Akshat Shah

  • Wistron Corp (3231 TT) is raising around US$1.5bn, selling 250m shares via a GDR offering. Proceeds will be used to procure raw materials overseas.
  • Similar to previous GDR listings, the firm has undergone a long drawn out process prior to launching the deal, having to jump through a number of board/shareholder/regulatory approval loops.
  • In this note, we run the deal through our ECM framework and comment on deal dynamics.

SB Energy Pre-IPO: Tearsheet

By Ke Yan, CFA, FRM

  • SB Energy, an AI data center and power infrastructure developer, has filed its S1 for a Nasdaq listing. JPM, GS and MS are the lead bankers.
  • We look at the company’s core segments: Standalone Power and Data Centers.
  • We then look at the company’s financial profile, loss-making status, pre-IPO valuation and investor backing.

Aequitas: LuxNet GDR Early Look – Smallest Offering in the GDR Pipeline This Year

By Akshat Shah

  • Luxnet Corp (4979 TT) is looking to raise up to US$158m in its upcoming global depository receipts (GDRs) offering.
  • On 22nd July 2026, LuxNet announced that it had received its board’s approval to sell around 6-8m common shares via a GDR offering.
  • Similar to previous GDR listings, the deal is a long drawn out process with the firm required to jump through a number of board/shareholder/regulatory approval loops.

Aequitas: Shenzhen Longsys Electronics A/H Trading – One of the Lowest Insti Demand

By Sumeet Singh

  • Shenzhen Longsys Electronics (301308 CH) (SLE), a branded independent semiconductor memory product enterprise, raised around US$1,050m in its H-share listing.
  • SLE designs, develops, manufactures and sells a comprehensive portfolio of memory products for edge AI and traditional consumer, enterprise and industrial applications.
  • We have looked at the past performance and likely A/H premium in our previous note. In this note, we talk about the trading dynamics.

Longsys (江波龙) IPO Trading

By Ke Yan, CFA, FRM

  • Longsys, a branded memory-module maker, raised HKD 6,803.2m (USD 867.7m) in net proceeds from its Hong Kong IPO and will list on the SEHK on Tuesday, September 8, 2026.
  • In our previous note, we looked at the company’s deal terms, cornerstone and sponsor track records, and valuation.
  • In this note, we provide an update for the IPO before its trading debut.

Aequitas: Elice IPO Pricing – Might Be Popular with Retail Investors

By Nicholas Tan

  • Elice Group (ELICE KS) is looking to raise up to US$145m in its upcoming Korean IPO.
  • It recently transitioned to being a neocloud in South Korea.
  • In this note, we examine the IPO dynamics, and look at the firm’s valuation.

IPO Databook: Shenzhen Forms Syntron Information (HK) – Sep 2026

By αSK IPO Databooks

  • Shenzhen Forms Syntron Information Co., Ltd. is a Greater Bay Area fintech service provider, delivering software development, consulting, and system integration services to financial institutions. It holds seven patents and.
  • Over 90% of the workforce are technical professionals, and the Hong Kong fintech market is projected to reach RMB44.0 billion by 2030.
  • In 2025, revenue was RMB631,068 thousand and profit for the year was RMB74,281 thousand. Net current assets were RMB1,258,798 thousand as of March 31, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Pre-IPO Triapex Laboratories – Future Performance Will Lack Stability

By Xinyao (Criss) Wang

  • Unlike traditional CROs which act as external service providers to handle scattered tasks, TRIAPEX is strategic R&D partner for clients,offering end-to-end services covering entire process from drug discovery to NDA.
  • Monkeys, as biological assets, have their fair value changes directly recorded in profit statement, acting as an “amplifier” for TRIAPEX’s performance. This will lead to significant fluctuations in future performance.
  • TRIAPEX’s valuation would be lower than Joinn Lab. The final valuation depends on  the price trend of laboratory monkeys and the overall valuation of biopharmaceutical sector in Hong Kong stock market.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars